Video | July 29, 2020

How Has COVID-19 Stalled Drug Development

Source: Life Science Leader

Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmaceutical companies (view full video here). In this portion, Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics (NASDAQ: OVID), and Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), discuss how the pandemic has stalled some drug development efforts.